- Home
- ACAD vs LBTYA Comparison
ACAD vs LBTYA Comparison
Compare ACAD & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- LBTYA
- Stock Information
- Founded
- ACAD 1993
- LBTYA 2004
- Country
- ACAD United States
- LBTYA Bermuda
- Employees
- ACAD N/A
- LBTYA N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- LBTYA Cable & Other Pay Television Services
- Sector
- ACAD Health Care
- LBTYA Telecommunications
- Exchange
- ACAD Nasdaq
- LBTYA Nasdaq
- Market Cap
- ACAD 3.8B
- LBTYA 3.6B
- IPO Year
- ACAD 2004
- LBTYA N/A
- Fundamental
- Price
- ACAD $20.98
- LBTYA $9.96
- Analyst Decision
- ACAD Buy
- LBTYA Buy
- Analyst Count
- ACAD 18
- LBTYA 5
- Target Price
- ACAD $27.71
- LBTYA $15.92
- AVG Volume (30 Days)
- ACAD 2.0M
- LBTYA 1.6M
- Earning Date
- ACAD 08-05-2025
- LBTYA 08-01-2025
- Dividend Yield
- ACAD N/A
- LBTYA N/A
- EPS Growth
- ACAD N/A
- LBTYA N/A
- EPS
- ACAD 1.37
- LBTYA N/A
- Revenue
- ACAD $996,283,000.00
- LBTYA $4,421,800,000.00
- Revenue This Year
- ACAD $13.39
- LBTYA $8.29
- Revenue Next Year
- ACAD $10.59
- LBTYA $0.74
- P/E Ratio
- ACAD $15.33
- LBTYA N/A
- Revenue Growth
- ACAD 22.42
- LBTYA 32.44
- 52 Week Low
- ACAD $13.40
- LBTYA $9.03
- 52 Week High
- ACAD $25.23
- LBTYA $21.56
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- LBTYA 50.56
- Support Level
- ACAD $20.75
- LBTYA $9.87
- Resistance Level
- ACAD $23.09
- LBTYA $10.26
- Average True Range (ATR)
- ACAD 0.78
- LBTYA 0.23
- MACD
- ACAD -0.20
- LBTYA 0.02
- Stochastic Oscillator
- ACAD 9.83
- LBTYA 40.14
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in several telecom companies in the UK, the Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies, and has pursued a strategy since 2016 to merge or partner with mobile-network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.